BioTuesdays

Tag - Brookline

Hepion Pharmaceuticals

Brookline starts Hepion Pharma at buy; PT $12

Brookline Capital Markets launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with a “buy” rating and $12 price target. The stock closed at $3.39 on Nov. 21. Hepion is developing CRV431, a novel pleiotropic...

Brookline starts SCYNEXIS at buy; PT $5

Brookline Capital Markets launched coverage of SCYNEXIS (NASDAQ:SCYX) with a “buy” rating and $5 price target. The stock closed at $1.07 on Aug. 19. Analyst Kumaraguru Raja writes that SCYNEXIS’ lead product candidate...

Brookline starts Vaxart at buy; PT $6

Brookline Capital Markets launched coverage of Vaxart (NASDAQ:VXRT) with a “buy’ rating and $6 price target. The stock closed at 66 cents on Aug. 14. Vaxart is focused on oral, recombinant vaccines that are expected to...

Cellectar Bio

Brookline starts Cellectar Biosciences at buy; PT $6

Brookline Capital Markets launched coverage of Cellectar Biosciences (NASDAQ:CLRB) with a “buy” rating and price target of $6. The stock closed at $2.14 on July 29. Cellectar has a unique cancer target delivery platform...

Brookline starts Progenics Pharma at buy; PT $10

Brookline Capital Markets initiated coverage of Progenics Pharmaceuticals (NASDAQ:PGNX) with a “buy” rating and $10 price target. The stock closed at $5.25 on July 29. “We expect that Progenics is well poised to ramp up...

Brookline starts Heat Biologics at buy; PT $8

Brookline Capital Markets launched coverage of Heat Biologics (NASDAQ:HTBX) with a “buy” rating and $8 price target. The stock closed at 52 cents on July 29. Heat Biologics has cell-therapy platforms called ImPACT and...

Brookline starts Veru at buy; PT $12

Brookline Capital Markets initiated coverage of Veru (NASDAQ:VERU) with a “buy” rating and $12 price target. The stock closed at $2.23 on July 29. “In our view, VERU-111 and zuclomiphene have potential to be value...

Brookline starts Celsion at buy; PT $9

Brookline Capital Markets launched coverage of Celsion (NASDAQ:CLSN) with a “buy” rating and $9 price target. The stock closed at $1.79 on July 25. Celsion is focused on clinical-stage oncology products and platform...

Brookline starts Chiasma at buy; PT $15

Brookline Capital Markets initiated coverage of Chiasma (NASDAQ:CHMA) with a “buy” rating and $15 price target. Chiasma is developing Mycapssa as potential maintenance treatment for adults with acromegaly, a hormonal...

Subscribe

Sign up to our weekly BioTuesdays newsletter.